Squarepoint
CTMX icon

Squarepoint’s CytomX Therapeutics CTMX Stock Holding History

Squarepoint’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-109,000
Closed -$129K – 5097
2024
Q3 		$129K Buy
+109,000
New +$138K ﹤0.01% 3817
2024
Q2 		– Sell
-47,000
Closed -$102K – 4156
2024
Q1 		$102K Buy
+47,000
New +$86.7K ﹤0.01% 3793

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VR Adviser
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Squarepoint's CTMX Position: Q2 2026 in Review

Squarepoint reduced its CytomX Therapeutics (CTMX) stake by 54% in Q2 2026, selling an estimated $493K and leaving 112,152 shares worth $421K. The position accounts for ﹤0.01% of the portfolio, ranked #3555.

Squarepoint first reported a position in CTMX in Q4 2016 and has held it in 34 quarters since. The position peaked at $4.74M in Q2 2021. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Squarepoint held 112,152 shares of CytomX Therapeutics worth $421K as of Q2 2026.
  • Squarepoint sold 129,063 CytomX Therapeutics shares in Q2 2026, an estimated $493K.
  • CytomX Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3555 holding.
  • Squarepoint first reported a position in CytomX Therapeutics in Q4 2016 and has held it in 34 quarters since.
  • Squarepoint's CytomX Therapeutics position peaked at $4.74M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.